Equities Analysts Issue Forecasts for Harrow Q3 Earnings

Harrow, Inc. (NASDAQ:HROW) – Stock analysts at B. Riley lowered their Q3 2025 EPS estimates for shares of Harrow in a report issued on Tuesday, September 30th. B. Riley analyst M. Mamtani now forecasts that the company will earn $0.33 per share for the quarter, down from their previous estimate of $0.36. B. Riley currently has a “Buy” rating and a $74.00 price target on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. B. Riley also issued estimates for Harrow’s FY2025 earnings at $0.82 EPS, FY2026 earnings at $2.86 EPS and FY2027 earnings at $4.34 EPS.

HROW has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $64.00 target price on shares of Harrow in a research note on Monday, September 29th. BTIG Research reaffirmed a “buy” rating and set a $63.00 price objective on shares of Harrow in a research report on Wednesday, September 24th. William Blair assumed coverage on shares of Harrow in a research note on Tuesday, June 10th. They issued an “outperform” rating on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a research note on Saturday, September 27th. Finally, Cantor Fitzgerald assumed coverage on shares of Harrow in a report on Friday, July 11th. They set an “overweight” rating and a $76.00 price target on the stock. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $68.50.

Harrow Stock Down 4.8%

NASDAQ:HROW opened at $45.43 on Friday. The business’s fifty day moving average price is $39.56 and its 200 day moving average price is $32.24. The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of -181.72 and a beta of 0.27. The company has a current ratio of 0.62, a quick ratio of 0.58 and a debt-to-equity ratio of 0.78. Harrow has a 1-year low of $20.85 and a 1-year high of $59.23.

Harrow (NASDAQ:HROW) last released its earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.23. The company had revenue of $63.74 million during the quarter, compared to analyst estimates of $64.23 million. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%. Harrow has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On Harrow

Institutional investors have recently added to or reduced their stakes in the stock. Voya Investment Management LLC boosted its stake in Harrow by 4,035.5% in the 1st quarter. Voya Investment Management LLC now owns 381,461 shares of the company’s stock valued at $10,147,000 after buying an additional 372,237 shares in the last quarter. Diametric Capital LP bought a new position in shares of Harrow during the second quarter valued at $4,748,000. Bank of America Corp DE lifted its holdings in shares of Harrow by 266.8% during the second quarter. Bank of America Corp DE now owns 213,448 shares of the company’s stock valued at $6,519,000 after acquiring an additional 155,258 shares during the period. Divisadero Street Capital Management LP acquired a new stake in shares of Harrow in the 2nd quarter valued at $4,293,000. Finally, Invesco Ltd. grew its holdings in shares of Harrow by 967.6% in the 2nd quarter. Invesco Ltd. now owns 150,948 shares of the company’s stock worth $4,610,000 after purchasing an additional 136,809 shares during the last quarter. 72.76% of the stock is owned by institutional investors and hedge funds.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.